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Abstract. Radon is one of the most powerful carcinogens, 
particularly in terms of lung cancer onset and development. 
miRNAs may be considered not only as markers of the ongoing 
tumorigenesis but also as a hallmark of exposure to radiation, 
including radon and its progeny. Therefore, the purpose of the 
present study was to estimate the value of plasma miR-19b-3p 
level as the prospective marker of the response to radon 
exposure in lung cancer pathogenesis. A total of 136 subjects 
were examined, including 49 radon-exposed patients with lung 
cancer, 37 patients with lung cancer without radon exposure 
and 50 age/sex matched healthy controls. Total RNA from 
blood samples was extracted and used to detect miR-19b-3p 
expression via reverse transcription quantitative-polymerase 
chain reaction. The 2-ΔΔCq method was used to quantify the 
amount of relative miRNA. The plasma level of p53 protein was 
determined using a Human p53 ELISA kit. Plasma miR-19b-3p 
level was significantly higher in the patients with lung cancer 
groups, compared with the healthy control group (P<0.0001). 
No other statistically significant differences were determined 
in the expression level of plasma miR-19b-3p between patients 
diagnosed with lung cancer exposed to radon and not exposed to 
radon. The expression level of free circulating miR-19b-3p was 
higher in the group of non-smoking patients with lung cancer, 
compared with smokers with lung cancer. The miR-19b-3p 
was 1.4-fold higher in non-smokers than in smokers (P<0.05). 
No association between plasma levels of p53 protein and 
miR-19b-3p freely circulating in patients with lung cancer was 
observed. No other statistically significant differences were 
determined in the plasma p53 protein level between patients 
diagnosed with lung cancer exposed and not exposed to radon. 
These results indicated that detection of miR-19b-3p levels in 
plasma potentially could be exploited as a noninvasive method 
for the lung cancer diagnostics. However, this miRNA is not 
suitable as the precise marker for radon impact.
Introduction
Lung cancer causes almost 1.3 million mortalities/year 
globally (1). Cigarette smoke and radon exposure are the 
major risk factors for lung cancer (2). Primary prevention is 
fundamental in lung cancer, which is a tumor characterized by 
a long latency period (3). Circulating miRNAs may be proposed 
as biomarkers for diagnosis, prognosis or monitoring curative 
effects in various cancer types, including lung cancer (4). 
In cells, miRNAs are present as short (18-22 nucleotides), 
non-coding molecules involved in post-transcriptional gene 
regulation, mRNA degradation and/or translation inhibition (5). 
Aberrant expression of miRNAs has been established in diverse 
tumor types, including hepatocellular carcinoma (6), breast (7), 
stomach (8), prostate (9) and lung cancer (10).
A numbers of studies have demonstrated that increased 
expression of miR-19 confers negative prognosis for patients 
with lung cancer (11-13). According to these studies, the 
miR-19 family is responsible for epithelial-mesenchymal 
transformation of cells, which, in turn, further facilitates the 
processes of cell migration and invasion.
Recent data indicated that miRNAs are engaged in the 
regulation of cellular processes induced by radiation and, 
consequently, miRNAs can potentially be used as biomarkers 
to assess the degree of exposure to radiation in humans (14). 
There is evidence that the expression profile of a number of 
miRNAs, including miR19b-3p in human bronchial epithelium 
BEAS2B cells, have been altered upon exposure to radon (15).
A key role in maintaining the genome stability pertains to 
p53, including response to damage caused by radiation (16). 
TP53 mutation was identified in the development of tumors of 
a number of localizations, including lung cancer (17). Specific 
‘hotspot’ mutations in cancer-relevant genes have been 
described in radon-induced lung cancer (16,18-20).
Different studies have indicated that TP53 can directly 
suppress the expression of oncogenic miRNAs, and as a tran-
scription factor, can activate the expression of oncosuppressor 
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miRNAs (21-23). However, the latest data also indicated the 
presence of miRNA-mediated post-transcriptional regula-
tion of TP53 in mammalian cells (24). Fan et al (24) have 
demonstrated that TP53 is the target of miR-19b and the over-
expression of miR-19b in cancer cells leads to a decrease in the 
level of the p53 protein and its targets, Bax and p21 proteins.
Nevertheless, despite the copious amounts of evidence 
supporting the association between p53 and miRNA in lung 
cancer, the pathogenic mechanisms underlying this process 
remain largely unclear particularly concerning the epigenetic 
modulation. This is particularly true for radon-induced lung 
cancer (25,26).
The aim of the present study was to determine the altera-
tions in free circulating miR-19b and the level of p53 protein in 
the plasma of patients with lung cancer exposed to high doses 
of radon.
Materials and methods
Study design and population. A total of 136 subjects was 
examined, including: i) 49 radon-exposed patients with 
lung cancer (RLC); ii) 37 patients with lung cancer without 
radon exposure (LC); and iii) 50 healthy controls (C). The 
radon-exposed patients with lung cancer comprised 39 males 
and 10 females with a mean age of 67.8±1.78 years. The group 
of lung cancer patients without radon exposure consisted of 
31 males and 6 females with a mean age of 57.42±2.34 years. 
Healthy control was represented by 39 males and 11 females 
with a mean age of 60.7±1.96 years.
All patients with primary lung cancer were diagnosed 
between April 2015 and September 2016 at the Astana 
Oncology Center (Astana, Kazakhstan) and at the Akmola 
Region Oncology Hospital (Kokshetau, Kazakhstan). All 
cases were newly diagnosed, previously untreated and histo-
logically confirmed. Clinical stage was classified according 
to the sixth edition of the Tumor‑Node‑Metastasis classifica-
tion of the International Union Against Cancer (27). Controls 
were matched for sex, age and smoking status to patients with 
lung cancer, according to characteristics of subjects which 
are reported in Table I. At recruitment, each participant was 
interviewed to obtain detailed information on age, life history 
of tobacco use and occupational activities.
All information regarding participants was rendered 
anonymous following data and blood sample collection. 
Informed consent was obtained from each study participant 
prior to interview and blood collection. The present study 
was approved by the Ethical Committee of the Semey State 
Medical University (Semey, Kazakhstan; approval no. 2).
RNA extraction from blood. A 10 ml sample of whole 
peripheral blood was collected from each subject into EDTA 
containing tubes. Blood was centrifuged at 3,000 x g for 
10 min at room temperature and supernatant stored in aliquots 
at ‑80˚C. Total RNA from 200 µl plasma was isolated using 
the MiRCURY™ RNA Isolation kit‑Biofluids (cat no. 300112; 
Exiqon A/S, Vedbaek, Denmark), in accordance with the 
manufacturer's protocol. The amount and purity of extracted 
RNA were evaluated using a fiber optic spectrophotometer 
(Nanodrop™ ND-1000; Nanodrop Technologies; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA) in accordance 
with the manufacturer's protocols, and the 230/260 (<0.50) 
and 260/280 (>1.85) absorbance ratios were calculated. The 
RNA structural integrity was evaluated by capillary electro-
phoresis using a RNA bioanalyzer (Bioanalyzer Agilent 2100; 
Agilent Technologies, Inc., Santa Clara, CA, USA) equipped 
with a RNA oligonucleotide chip (RNA 6000 Nano Ladder 
Chip; Agilent Technologies, Inc.). The miRNA amounts were 
accurately standardized among blood serum samples for 
microarray and quantitative polymerase chain reaction (qPCR) 
analyses using the Qubit™ 3.0 Fluorometer (Thermo Fisher 
Scientific, Inc.).
miR‑19 analysis by qPCR. The expression levels of miR-19b-3p 
was determined by evaluating the level of fluorescence 
emitted by SYBR® Green tracer (cat no. 203403; Exiqon A/S, 
Denmark). SYBR‑Green fluorescent tracer was used to identify 
PCR amplicons whose identity was checked by melting curve 
analysis according to previously published procedures (28). 
MiRCURY LNA™ UNIVERSAL RT microRNA PCR kit, 
including miR-19b-3p-specific primers (cat no. 204450; 
Exiqon A/S, Vedbaek, Denmark) and primers for the reference 
gene RNU6B (cat no. 203907; Exiqon A/S) for reverse tran-
scription (RT)-qPCR, was used to amplify miRNAs. cDNAs 
were prepared using Universal synthesis kit (cat no. 203301; 
Exiqon A/S) according to the manufacturer's instructions. 
PCR amplification was performed in the CFX96 Touch™ 
Real-Time PCR Detection System (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). Each reaction was carried out using 
4 µl of cDNA, 1 µl of PCR primer mix and 5 µl SYBR‑Green 
PCR Master mix (cat nos. 204450 and 203403 respectively; 
Exiqon A/S, Denmark) in a final 10 µl volume. The RT‑qPCR 
was performed at 95˚C for 10 min for one cycle, followed by 
40 cycles of 95˚C for 10 sec and 60˚C for 60 sec. The speci-
ficity of PCR products was evaluated by the melting curve 
analysis. Gene expression was normalized to RNU6B. All 
reactions were carried out in triplicate, and the 2-ΔΔCq method 
(ΔCq=CTmiR-CTU6) was used to quantify the relative miRNA 
amount (29).
Exposure assessment. Measurement of radon activity was 
conducted in accordance with the Rapid Measurement Method 
of radon and thoron (30) using a Canary 222 Digital Electronic 
Radon Gas Monitor (LR-03) radiometer (Corentium AS, Oslo, 
Norway). The measurement of radon concentration was carried 
out at the homes of recruited patients in rooms previously 
unventilated for at least 24 h. In each room, radon in the air 
was measured for seven days and the average value was used 
for further calculations.
The annual effective dose (H) was calculated according 
to the formula (30): H (mSv/y)=C x F x O x T x D; where 
C stands for the average radon concentration Bq/m3, F is the 
equilibrium factor for indoor that is set as 0.4, O is the occu-
pancy factor taken as 0.8, T is time in h in a year (8,760 h/y) 
and D is the dose conversion factor, 1.4x10-8 Sv/Bq/m3 h.
Determination of p53 protein in plasma. The plasma level of 
p53 protein was determined using an ELISA kit (Human p53 
ELISA kit; cat no. ab46067; Abcam, Cambridge, UK). The 
samples were added to 96-microtiter wells pre-coated with the 
p53 monoclonal antibody from the kit and incubated at room 
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temperature for 2 h. Samples and biotinylated p53 monoclonal 
antibody were incubated for 1 h at room temperature. Following 
washing three times with 200X Wash buffer from the kit, the 
enzyme Streptavidin-HRP (also from the Human p53 ELISA 
kit), which binds the biotinylated antibody, was added and 
incubated for 30 min with washes performed three times with 
200X Wash buffer from the kit according to the protocol of 
the manufacturer. Chromogen TMB (3,3',5,5;-tetramethyl-
benzidine) substrate solution was added inducing a colored 
reaction product. The absorbance at 450 nm of each well was 
determined using a microplate reader (Asys Expert microplate 
reader; Biochrom, Ltd., Cambridge, UK). All samples were 
measured in triplicate.
Determination of cotinine in plasma. In order to verify 
smoking status of the individuals, blood plasma cotinine 
was utilized as a marker. The cotinine level was determined 
using an ELISA kit (Cotinine ELISA kit; cat no. KA0930; 
Abnova, Taipei, Taiwan) performed according to the manu-
facturers' protocols. Briefly, samples and cotinine enzyme 
conjugate were added to the wells coated with anti-cotinine 
antibody and horse peroxidase colorimetric reaction 
performed. Unbound cotinine and cotinine enzyme conju-
gate were washed three times with 300 µl 1X Wash Buffer, 
also from the Cotinine ELISA kit. The intensity of color 
(absorbance wavelength 450 nm) was inversely proportional 
to the concentration of cotinine in the samples. A standard 
curve was prepared associating color intensity with the 
concentration of the cotinine.
Statistical analysis. All statistical analyses were performed 
using GraphPad Prism 6 software (GraphPad Software, Inc., 
La Jolla, CA, USA). All data are presented as mean ± SD. 
Differences between groups were assessed using the Tukey's 
post hoc test after one-way analysis. P<0.05 was considered 
to indicate a statistically significant difference; *P<0.05; 
**P<0.01; ***P<0.001; and ****P<0.0001. χ2 was used to calculate 
the statistical significance in Table I.
Results
Effective annual radon exposure dose and decay product 
inhalation. The overall exposure to radon evaluated at the 
homes of monitored subjects is reported in Table II. The 
table represents the home addresses of the patients with lung 
cancer living on the territory with a level above the permis-
sible concentration, where radon levels were measured, and 
also demonstrated a level of equivalent equilibrium volume 
activity of radon (EEVA) and effective exposure dose for the 
population.
According to the generally accepted opinion in the world 
scientific community, the distribution of EEVA parameters 
obeys the lognormal law (30); therefore, the median value was 
used as the average value for calculating the exposure power 
of radon and its decay products. The characteristics of the data 
array and the parameters of the lognormal distribution are 
depicted in Table III. Thus, the average effective annual dose 
for patients diagnosed with lung cancer living in the areas with 
a high level of EEVA was 4.55 mSv/y. Participants in the study 
selected for control groups (C and LC) lived in areas with a low 
level of EEVA. These areas were determined according to the 
results reported in a previous study (15). The EEVA data used 
to calculate the average effective annual dose for participants 
in the control group study (C and LC) are depicted in Table IV. 
Thus, the average effective annual dose for study participants 
living in areas with a low level of EEVA was 0.88 mSv/y.
miR‑19b‑3p expression level in the plasma of patients with 
lung cancer with and without radon exposure. The total 
circulating miRNA was isolated from blood plasma using the 
protocol aforementioned and divided to three groups: Patients 
diagnosed with lung cancer living in areas with a radon concen-
tration below 200 Bq/m3 for ≥5 years; patients diagnosed with 
lung cancer who had been exposed to high doses of radon for 
5 years; and a control group consisting of healthy individuals, 
who did not have pulmonary pathology and lived in a EEVA 
area with <200 Bq/m3. The expression levels of miRNA-19b-3p 
Table I. Characteristics of the subjects participating in the present study.
Characteristics Variables LC, n=37 (%) RLC, n=49 (%) P-value C, n=50 (%)
Sex Male 31 (84) 39 (80) 0.78 39 (78)
 Female 6 (16) 10 (20)  11 (22)
Age, years ≤60 18 (49) 12 (24) 0.04 21 (42)
 >60 18 (49) 33 (67)  29 (58)
 Unknown 1 (3) 4 (8)  -
Stage of cancer I 7 (19) 4 (8) 1.0 -
 II-IV 22 (59) 35 (71)  -
 Unknown 8 (22) 10 (20) -
Smoking status Non-smokers 9 (24) 24 (49) 0.01 41 (82)
 Smokers 21 (57) 13 (27)  8 (16)
 Former Smokersa  7 (19) 12 (24) 1 (2)
aPatients having stopped smoking <6 months ago. RLC, patients with lung cancer exposed to radon; LC, patients with lung cancer without 
exposure to radon; C, control group.
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in all three groups were depicted in Fig. 1. miR-19b-3p expres-
sion levels in patients of the RLC group were 6.5 times higher 
(P<0.0001) than in the C group. miR-19 expression levels in 
the LC group was 6.9 times increased (P<0.0001), compared 
with those detected in the C group. Comparative analysis of 
the relative miR-19b-3p expression level in the RLC group vs. 
the LC group indicated that the miR‑19b‑3p expression profile 
in both groups did not differ significantly.
miR‑19b‑3p expression level in the plasma associated with 
smoking habits. The association of miR-19b-3p expression with 
smoking status was examined. The results of the present study 
demonstrated that miR-19b-3p expression levels do not differ 
in patients with lung cancer with or without radon exposure, 
and these groups were combined into one ‘patients with lung 
cancer’ group. This group was divided into current smokers 
and non-smokers regardless of radon exposure. Cotinine levels 
<10 ng/ml was considered as an indicator of the absence of 
current smoking.
The ‘Smokers’ group consisted of 34 people, and the 
‘Non-smokers’ group 33 people. Former smokers (subjects 
having stopped smoking <6 months ago) have been excluded 
from any of these groups (19 subjects). Furthermore, 
healthy control group (50 subjects) have been not included 
to this particular analysis due to, according to the previous 
experiments, miR‑19b‑3p expression level was significantly 
lower in the control group than in two groups with lung 
cancer diagnosis, that is, these groups are incompatible. As 
it can be observed from Fig. 2, the level of free circulating 
miR-19b-3p is higher in plasma in the group of non-smoking 
patients with lung cancer, compared with smokers. The 
mean plasma miR-19b-3p expression level was 6.45±0.4 in 
the ‘Non‑smokers’ group in comparison with the ‘Smokersʼ 
group, where the mean miR-19b-3p expression level was 
4.74±0.5, miR-19 being 1.4-fold higher in non-smokers than 
in smokers (P<0.05).
Table II. Overall air radon exposure of the premises and the 
effective exposure dose for the population.
Facility index
where EEVA  Average value
measurements  of EEVA, Annual effective
were taken Bq/m3 dose, mSv/y
  1 529 20.76
  2 51.2 2
  3 40.4 1.59
  4 84.5 3.32
  5 133 5.22
  6 116 4.55
  7 135 5.3
  8 54 2.12
  9 44 1.73
10 617 24.2
11 118 4.63
12 119 4.67
13 78 3.06
14 196 7.69
15 716 28.1
16 450 17.66
17 277 10.87
18 193 7.57
19 350 13.74
20 210 8.24
21 189 7.42
22 558 21.9
23 420 16.48
24 17 0.67
25 140 5.49
26 70 2.75
27 18 0.71
28 44 1.73
29 178 6.99
30 30 1.18
31 11 0.43
32 75 2.94
33 64 2.51
34 36 1.41
35 315 12.36
36 525 20.6
37 8 0.31
38 190 7.46
39 15 0.59
40 10 0.39
41 65 2.55
42 407 15.92
43 75 2.94
44 105 4.12
45 505 19.82
46 36 1.41
47 22 0.86
EEVA, equivalent equilibrium volume activity.
Table IV. Number of measurements and EEVA study results 
for areas with permissible radon concentrations. 
Parameters Values
Number of measurements 86
Minimum, Bq/m3 2
Maximum, Bq/m3 135
Median, Bq/m3 22.5
Table III. Number of measurements and EEVA study results 
for areas with high levels of radon. 
Parameters Values
Number of measurements    47
Minimum, Bq/m3     8
Maximum, Bq/m3 716
Median, Bq/m3 116
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p53 protein in plasma of patients with lung cancer as 
associated with radon exposure. The results of the p53 
protein measurement in plasma are given in Table V repre-
senting minimum, maximum, median and mean values. p53 
protein levels of the LC were determined in a range from 
5.17-36.81 U/ml, with a median value of 15.24 U/ml and the 
mean of 17.92±1.53 U/ml. RLC demonstrated the highest 
plasma p53 in the present study. In this group, the plasma 
levels of p53 had a range from 0.1-26.94 U/ml, median value 
of 13.0 U/ml and mean of 18.76±3.31 U/ml. The p53 protein 
has not been detected in plasma in 16% of the samples from 
C group. In 84% of samples from group C, the plasma levels 
of p53 were determined to range from 1.96-39.64 U/ml, with a 
median of 6.49 U/ml and mean value of 8.646±1.25 U/ml. The 
p53 plasma levels in the LC group were 2 times higher than 
in those of healthy subjects (P<0.05; Fig. 3). The p53 protein 
level was also 2 times higher in radon-exposed patients with 
lung cancer than in healthy volunteers (P<0.01). There were no 
significant differences in p53 protein concentrations between 
LC and RLC (P=0.265). However, there was no association 
between the level of miR-19b-3p and the plasma p53 level in 
patients with lung cancer, as indicated via regression analysis 
(r=0.06; P=0.24).
Discussion
Recent studies have reported that non-coding RNA (ncRNA) 
may serve a critical role in regulating different cancer 
types (31,32). These ncRNAs are divided into housekeeping 
ncRNAs and regulatory ncRNAs (33). The regulatory 
ncRNAs have emerged as critical regulators of gene expres-
sion in normal and disease states (34). This heterogeneous 
group depending on their size can be divided into lncRNAs 
(≥200 nucleotides) and small ncRNAs (<200 nucleotides) (35). 
miRNAs represent the most studied small ncRNAs. These 
molecules predominantly bind to 3'-UTRs of mRNAs to 
mediate post-transcriptional gene silencing (36). A number of 
studies have identified aberrant miRNA expression in different 
types of cancer (35). Circulating miRNAs, passively leaked 
or actively transported outside cells, can be stably detected 
in blood and may be proposed as biomarkers for diagnosis, 
prognosis or monitoring curative effect in various cancer 
types, including lung cancer (37). Since miRNAs are involved 
in the development and progression of lung cancer, there is a 
particular interest in miRNAs not only as novel biomarkers 
but also as potential tools for treatment (38).
In the present study, changes in the level of miR-19b-3p 
expression were analyzed, which serve a significant role in 
the development of a number of cancer types (39,40), as well 
as in metastasis (41) and tumor response to drug therapy (42). 
A miRNA panel including miR-19b-3p in peripheral plasma 
was identified and proposed as a biomarker in diagnosis of 
adenocarcinoma lung cancer as reported by Zhou et al (43). 
Furthermore, obtained results are consistent with the previous 
data of Li et al (41), who discovered that miR-19b expression 
was significantly higher in lung adenocarcinoma cell lines 
Table V. Level of p53 protein in the plasma of RLC, LC and C. 
Subjects n Min, U/ml Max, U/ml Med, U/ml Mean, U/ml P-value
RLC 49 0.1 126.94 13 18.76 <0.01
LC 37 5.17 36.81 15.24 17.92 <0.05
C 50 1.96 39.64 6.49 8.646
RLC, patients with lung cancer exposed to radon; LC, patients with lung cancer without exposure to radon; C, control group. 
Figure 1. Relative expression level of miR-19b-3p in the plasma of RLC and 
LC in comparison with C. ****P<0.0001 vs. C. RLC, patients with lung cancer 
exposed to radon; LC, patients with lung cancer without exposure to radon; 
C, control group.
Figure 2. Relative miR-19b-3p expression level in the plasma of patients with 
lung cancer depending on the smoking status. *P<0.05 vs. Smokers.
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(A549), compared with the cell line of human lung epithelial 
cells. The present study has also demonstrated that a high 
level of miR-19b expression can promote the proliferation and 
migration of lung cancer cells (44). Additionally, miR-19-3p, 
miR‑21‑5p and miR‑221‑3p were significantly upregulated in 
exosomes extracted from peripheral plasma of patients with 
lung adenocarcinoma (43).
Epidemiological studies have provided strong evidence 
for associations between exposure to environmental factors 
and lung cancer (45,46). Risk factors for lung cancer include: 
Smoking; exposure to secondhand smoke; exposure to 
asbestos (47); and other carcinogens. Radon is the second 
leading cause of lung cancer among smokers and the leading 
cause among nonsmokers (2). A high level of radon has been 
observed in the North and East areas of Kazakhstan due to 
the natural radiation sources and the long-term and large-scale 
mining of uranium (48). Currently, there is no clear insight 
of the molecular mechanism underlying radon induced lung 
cancer (49).
Accordingly, the miRNA profile revealed a radon‑induced 
change in the miR-19b-3p expression in bronchial epithelial 
cells (BEAS2B). The level of miR-19b-3p expression increased 
by 17 times upon radon impact (15). Therefore, it can be 
assumed that this miRNA could be involved in the patho-
genesis of radon-induced lung cancer. However, comparative 
analysis of miR-19b-3p blood expression level in RLC and 
LC reveals no significant difference between the two groups. 
Thus, the obtained results indicated that miR19b-3p serves 
an important role in the malignant neoplasm development. 
However, according to the present study, this miRNA is inap-
propriate to be utilized as a hallmark of radon impact.
Another important aspect of the given study is the effect 
of smoking as the main risk factor for the development of 
lung cancer and on the level of miR-19 expression (50). It is 
logical to assume that if tobacco smoke is a carcinogen, and 
therefore the level of oncomir in smoking patients with lung 
cancer diagnosis should increase. However, in the present 
study the obtained results demonstrated the opposite. Thus, 
in the smoking group of patients with lung cancer, the 
expression level of miR‑19b‑3p was significantly lower than 
in the group of non-smokers. It is possible that this is not a 
specific reduction in the miR‑19b‑3p expression since tobacco 
smoke provokes a general decrease in all freely circulating 
miRNAs due to the inhibitory effect on the main enzyme of 
miRNA biogenesis, DICER (51). Furthermore, it has been 
reported that the alteration of miRNA expression induced by 
cigarette smoke has opposite effects in the lungs and blood, 
with the lungs downregulating miRNAs and miRNAs being 
upregulated in blood (52). This situation is associated with the 
inhibition of DICER processing induced by cigarette smoke 
exposure, which causes a blockage in miRNA maturation and 
release from cells into the blood stream of miRNA precursor 
in the absence of their mature counterpart (53).
miRNAs downregulated by mainstream cigarette smoke 
are miR-19b and miR-292, which are involved in the regulation 
of DICER, a key molecule in miRNA biogenesis, as demon-
strated by Balansky et al (54). However, in the present study 
there are a number of limitations: First, the level of miRNA 
circulating freely in the blood plasma was analyzed. The 
level of free circulating miRNAs can differ significantly from 
the level of the same miRNAs in the tissues due to different 
types of mammalian tissues varying in the profile of miRNAs 
expressed in them (55). An example of this case is let-7 miRNA, 
which serves a significant role in the embryonic development 
of the lung, and the expression of this miRNA remains at a 
high level in the postembryonic period (56). As Mendell (57) 
depicted, the miR-17-92 miRNA cluster, which includes 
miR-19, serves a crucial role in the embryonic development 
of the heart, lungs and immune system. Furthermore, the loss 
of the function of the miR-17-92 cluster leads to a decrease 
in the size of embryos and the immediate postnatal mortality 
of all animals (57). This is possibly due to pronounced lung 
hypoplasia and interventricular septum defects in the hearts of 
mice devoid of miR-17-92 (57).
The observations aforementioned are consistent with an 
earlier demonstration that miR-17-92 miRNA clusters usually 
have a high level of expression in the embryonic lung, and later 
its levels decrease as the mice matures (58). Furthermore, the 
transgenic expression of these miRNAs specifically in the 
pulmonary epithelium leads to severe developmental defects 
with increased proliferation and inhibition of epithelial cell 
differentiation (58). Despite the fact that exposure to tobacco 
smoke experiments in animal models lead to a decrease in 
body weight and have in general negative effect on cell prolif-
eration and survival, an opposite pattern has been observed 
in target tissues, including lungs distinguished by hyperplasia 
of pulmonary tissue (54). Considering the aforementioned, it 
appears necessary to investigate the tissue‑specific miR‑19b‑3p 
profile in the lungs of smokers and non‑smokers to improve 
the understanding of the role of this miRNA in the develop-
ment of lung cancer induced by smoking. The present study 
has demonstrated that the level of miR-19b-3p circulating in 
the blood plasma significantly decreases in smokers with lung 
cancer, and this is consistent with previous data, indicating the 
negative effect of tobacco smoke on proliferative activity in 
the body as a whole (59,60).
miR-19 is a key member of the miR-17/92 cluster, which 
targets several critical apoptosis associated genes, including 
TP53 (24). Fan et al (24) demonstrated that when miR-19b is 
transfected into HeLa cells, following 48 h, the p53 protein level 
is reduced by 50%, while the mRNA level remains unchanged. 
Figure 3. Level of plasma p53 of RLC and LC in comparison with C. *P<0.05 
LC vs. C, **P<0.01 RLC vs. C, patients with lung cancer exposed to radon; 
LC, patients with lung cancer without exposure to radon; C, control group.
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Indeed, miR-19b directly targets p53 by base-pairing to its 
3'UTR The TP53 gene was the first tumor‑suppressor gene to 
be identified. The p53 network, which present in all cells of 
the organism is normally ‘off’ (61). In the absence of damage 
to the genetic apparatus, the p53 protein is in an inactive state, 
and when DNA lesions occur, it becomes activated (62). The 
p53 protein is also activated by stimuli that remind those 
damages when p53 is active or are a signal regarding the 
unfavorable state of the cell (stress state) (63). The function of 
the p53 protein is to remove from the pool of replicating onco-
genetic cells (62). Consequently, it can be assumed that one 
of the mechanisms underlying the lung cancer development 
is a decrease in the level of the p53 protein due to targeting 
its mRNA by miR-19b-3p and is mediated by this process of 
prevention of apoptosis in cancer cells.
In the present study, utilizing the Human p53 ELISA kit, 
it was determined that the level of the p53 protein in plasma 
of patients with lung cancer exposed to high doses of radon 
as well as in those individuals living in areas with a permis-
sible concentration of EEVA, compared with the control group 
consisting of healthy people. The results of the present study 
have revealed that the level of p53 is significantly higher in 
both groups of patients diagnosed with lung cancer, while in a 
number of samples of healthy people it has not been detected 
at all. This data does not contradict the available data (64). 
According to a previous study (65), the level of antibodies 
against p53 in the blood serum increases with any pathology of 
the lung not only in malignant but even in benign tumors (65).
The present study paid close attention to two aspects. 
Firstly, whether there was a association between the p53 level 
and miR-19b-3p circulating freely in the blood plasma; addi-
tionally, the second aspect has concerned the issue of the effect 
of plasma p53 level on radon and its progeny.
The present study revealed no association between the 
plasma p53 and miR-19b-3p levels freely circulating in the 
blood plasma in patients with lung cancer. Thus, in both cases, 
the level of p53 protein and miR-19b-3p has been determined 
in the blood plasma and not in the lung tissue, so it cannot 
be concluded that these two components are not involved in 
a single mechanism underlying the malignant tumor onset 
in the lung. In addition, no other statistically significant 
differences have been determined in the plasma p53 protein 
level between RLC and LC. Also, the results of the present 
study are consistent with the data of other authors (66,67). In 
the studies of Schneider et al (67), no appreciably elevated or 
diminished p53 protein or anti-p53 antibodies values in serum 
of Former Uranium Miners was determined. Also, there was 
no association of these indicators with Working Level Months 
(WLM). Thereby, plasma p53 protein level is ineffective as 
a biomarker for the detection of lung cancer associated with 
radon and its progeny.
Collectively, these studies indicated that miR-19b-3p is not 
a suitable biomarker for radon-induced lung cancer. Despite 
the available data in the literature that overexpression of 
miR-19b observed in human cancer cells lines can diminish 
p53 protein levels, the present study did not determine any 
association between the plasma p53 and the miR-19b-3p levels 
freely circulating in the blood plasma in patients with lung 
cancer. Furthermore, any changes in the plasma p53 protein 
levels depending on the effect of radon were not determined. 
However, further research for biomarkers including miRNAs 
will provide a biomonitoring strategy to face health-risk in 
population living in radon-polluted areas and professionally 
exposed workers.
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